An international expanded access programme of everolimus: Addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy

I Bodrogi, The REACT Study Group

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
JournalEur J Cancer
Publication statusPublished - 29 Jul 2011

Cite this